Literature DB >> 16571645

Polymorphisms in the xylosyltransferase genes cause higher serum XT-I activity in patients with pseudoxanthoma elasticum (PXE) and are involved in a severe disease course.

S Schön1, V Schulz, C Prante, D Hendig, C Szliska, J Kuhn, K Kleesiek, C Götting.   

Abstract

BACKGROUND: Pseudoxanthoma elasticum (PXE) is a heritable connective tissue disorder caused by mutations in the ABCC6 gene. Fragmentation of elastic fibres and deposition of proteoglycans result in a highly variable clinical picture. The altered proteoglycan metabolism suggests that enzymes from this pathway function as genetic co-factors in the severity of PXE. Therefore, we propose the XYLT genes encoding xylosyltransferase I (XT-I) as the chain-initiating enzyme in the biosynthesis of proteoglycans and the highly homologous XT-II as potential candidate genes.
METHODS: We screened all XYLT exons in 65 German PXE patients using denaturing high performance liquid chromatography and analysed the influence of the variations on clinical characteristics.
RESULTS: We identified 22 variations in the XYLT genes. The missense variation p.A115S (XT-I) is associated with higher serum XT activity (p = 0.005). The amino acid substitution p.T801R (XT-II; c.2402C>G) occurs with significantly higher frequency in patients under 30 years of age at diagnosis (43% v 26%; p = 0.04); all PXE patients with this variation suffer from skin lesions compared to only 75% of the wild type patients (p = 0.002). c.166G>A, c.1569C>T, and c.2402C>G in the XYLT-II gene were found to be more frequent in patients with higher organ involvement (p = 0.04, p = 0.01, and p = 0.02, respectively).
CONCLUSIONS: Here we show for the first time that variations in the XYLT-II gene are genetic co-factors in the severity of PXE. Furthermore, the higher XT activity in patients with the exchange p.A115S (XT-I) indicates that this polymorphism is a potential marker for increased remodelling of the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16571645      PMCID: PMC2593031          DOI: 10.1136/jmg.2006.040972

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  31 in total

1.  Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II.

Authors:  C Götting; J Kuhn; R Zahn; T Brinkmann; K Kleesiek
Journal:  J Mol Biol       Date:  2000-12-08       Impact factor: 5.469

2.  Assessment of a rapid-cycle PCR assay for the identification of the recurrent c.3421C>T mutation in the ABCC6 gene in pseudoxanthoma elasticum patients.

Authors:  Christian Götting; Veronika Schulz; Doris Hendig; Alexander Grundt; Jens Dreier; Christiane Szliska; Thomas Brinkmann; Knut Kleesiek
Journal:  Lab Invest       Date:  2004-01       Impact factor: 5.662

3.  Pseudoxanthoma elasticum.

Authors:  K H Neldner
Journal:  Int J Dermatol       Date:  1988-03       Impact factor: 2.736

4.  Effect of selective enzymatic digestions on skin biopsies from pseudoxanthoma elasticum: an ultrastructural study.

Authors:  I Pasquali Ronchetti; M Baccarani Contri; C Pincelli; G M Bertazzoni
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

5.  Glycosaminoglycans of skin and urine in pseudoxanthoma elasticum: evidence for chondroitin 6-sulfate alteration.

Authors:  M O Longas; P Wisch; M G Lebwohl; R Fleischmajer
Journal:  Clin Chim Acta       Date:  1986-03-28       Impact factor: 3.786

6.  Pseudoxanthoma elasticum (PXE): ultrastructural and biochemical study on proteoglycan and proteoglycan-associated material produced by skin fibroblasts in vitro.

Authors:  R Tiozzo Costa; M Baccarani Contri; M R Cingi; I Pasquali Ronchetti; R Salvini; S Rindi; G De Luca
Journal:  Coll Relat Res       Date:  1988-01

7.  Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum.

Authors:  B Struk; L Cai; S Zäch; W Ji; J Chung; A Lumsden; M Stumm; M Huber; L Schaen; C A Kim; L A Goldsmith; D Viljoen; L E Figuera; W Fuchs; F Munier; R Ramesar; D Hohl; R Richards; K H Neldner; K Lindpaintner
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

8.  Anomalous structure of urinary glycosaminoglycans in patients with pseudoxanthoma elasticum.

Authors:  Francesca Maccari; Dealba Gheduzzi; Nicola Volpi
Journal:  Clin Chem       Date:  2003-03       Impact factor: 8.327

9.  Pseudoxanthoma elasticum: high calcium intake in early life correlates with severity.

Authors:  W A Renie; R E Pyeritz; J Combs; S L Fine
Journal:  Am J Med Genet       Date:  1984-10

10.  Pseudoxanthoma elasticum. Biochemical and ultrastructural studies.

Authors:  I Pasquali-Ronchetti; D Volpin; M Baccarani-Contri; I Castellani; A Peserico
Journal:  Dermatologica       Date:  1981
View more
  19 in total

Review 1.  ABCC6 as a target in pseudoxanthoma elasticum.

Authors:  András Váradi; Zalán Szabó; Viola Pomozi; Hugues de Boussac; Krisztina Fülöp; Tamás Arányi
Journal:  Curr Drug Targets       Date:  2011-05       Impact factor: 3.465

2.  Modifier genes in pseudoxanthoma elasticum: novel insights from the Ggcx mouse model.

Authors:  Alain Hovnanian
Journal:  J Mol Med (Berl)       Date:  2010-02-11       Impact factor: 4.599

3.  Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum.

Authors:  Qiaoli Li; Jennifer Larusso; Alix E Grand-Pierre; Jouni Uitto
Journal:  Clin Transl Sci       Date:  2009-12       Impact factor: 4.689

4.  In silico functional profiling of human disease-associated and polymorphic amino acid substitutions.

Authors:  Matthew Mort; Uday S Evani; Vidhya G Krishnan; Kishore K Kamati; Peter H Baenziger; Angshuman Bagchi; Brandon J Peters; Rakesh Sathyesh; Biao Li; Yanan Sun; Bin Xue; Nigam H Shah; Maricel G Kann; David N Cooper; Predrag Radivojac; Sean D Mooney
Journal:  Hum Mutat       Date:  2010-03       Impact factor: 4.878

5.  First identification and functional analysis of the human xylosyltransferase II promoter.

Authors:  Benjamin Müller; Christian Prante; Cornelius Knabbe; Knut Kleesiek; Christian Götting
Journal:  Glycoconj J       Date:  2012-08-11       Impact factor: 2.916

6.  Xylosyltransferase II is a significant contributor of circulating xylosyltransferase levels and platelets constitute an important source of xylosyltransferase in serum.

Authors:  Eduard Condac; George L Dale; Diane Bender-Neal; Beatrix Ferencz; Rheal Towner; Myron E Hinsdale
Journal:  Glycobiology       Date:  2009-04-23       Impact factor: 4.313

7.  The mineralization phenotype in Abcc6 ( -/- ) mice is affected by Ggcx gene deficiency and genetic background--a model for pseudoxanthoma elasticum.

Authors:  Qiaoli Li; Jouni Uitto
Journal:  J Mol Med (Berl)       Date:  2009-09-27       Impact factor: 4.599

8.  Ectopic mineralization of connective tissue in Abcc6-/- mice: effects of dietary modifications and a phosphate binder--a preliminary study.

Authors:  Jennifer LaRusso; Qiujie Jiang; Qiaoli Li; Jouni Uitto
Journal:  Exp Dermatol       Date:  2007-11-02       Impact factor: 3.960

9.  Elevated dietary magnesium prevents connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(-/-)).

Authors:  Jennifer LaRusso; Qiaoli Li; Qiujie Jiang; Jouni Uitto
Journal:  J Invest Dermatol       Date:  2009-01-01       Impact factor: 8.551

10.  Forward genetics defines Xylt1 as a key, conserved regulator of early chondrocyte maturation and skeletal length.

Authors:  Emily K Mis; Karel F Liem; Yong Kong; Nancy B Schwartz; Miriam Domowicz; Scott D Weatherbee
Journal:  Dev Biol       Date:  2013-10-23       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.